Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epix upbeat on mixed appeal decision from FDA, eyes late 2008 approval

This article was originally published in Clinica

Executive Summary

The US FDA has turned down Epix Pharmaceuticals' appeal for immediate approval of its MRI blood pool imaging agent, Vasovist, but has said that further trials of the product may no longer be necessary. A blinded re-read of the company's completed phase III trial data will now be carried out under the guidance of the agency. It the results prove positive, they could support an approval submission to the agency. The move has prompted the company to estimate an end-of-2008 approval decision for the product "if all goes well".

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048925

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel